Takeda delivers strong revenue and profit growth in FY2022

Japan’s largest drugmaker Takeda (TYO: 4502) has announced strong financial results for fiscal year 2022 (period ended March 31, 2023), delivering or exceeding management guidance, driven by the performance of its Growth & Launch Products.

Global revenues for the year were up 12.8% at 4,027 billion yen ($29.8 billion). Operating profit rose 6.4% to 490.5 billion yen, with net profit rising 37.8% to 317.0 yen. Earnings per share (EPS) increased 38.8% to 204 yen.

Christophe Weber, Takeda’s president and chief executive, commented: “FY2022 was another strong year for Takeda, reflecting successful execution against our business strategy and advancements in our innovative pipeline—enabling us to deliver truly transformative treatments to patients. Important pipeline milestones included the first approvals for our dengue vaccine Qdenga, positive late-stage readouts for TAK-755 and fazirsiran, and the acquisition of TAK-279 for immune-mediated diseases.